Total Parenteral Nutrition-induced Cholestasis Clinical Trial
Official title:
Compassionate Use of Omegaven IV Fat Emulsion in Infants With Life Threatening Parenteral Nutrition-associated Liver Disease (PNALD).
The purpose of the study is to provide use of Omegaven in children with life threatening Total Parenteral Nutrition (TPN) associated cholestasis when all other medical and surgical treatments/therapies have been either ineffective or not feasible in the treatment of this serious condition. This is a compassionate use protocol.
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02370251 -
Compassionate Use of Omegaven in Children
|
Phase 2/Phase 3 | |
Completed |
NCT01845116 -
Omegaven® in the Treatment of Parenteral Nutrition (PN) Induced Liver Injury
|
Phase 2 | |
Recruiting |
NCT01565278 -
Fish Oil for Patients With Liver Disease Due to Parenteral Nutrition
|
Phase 3 | |
Terminated |
NCT00816348 -
Compassionate Use of Omegaven IV Fat Emulsion
|
Phase 2 | |
Completed |
NCT02534077 -
Intravenous Fat Emulsion Comprised of Fish Oil in the Treatment of Parenteral Nutrition Induced Liver Injury in Infants
|
Phase 3 | |
Approved for marketing |
NCT02328768 -
Compassionate Use of Omegaven® for the Treatment of Intestinal Failure Associated Liver Disease in Children
|
||
Approved for marketing |
NCT02929303 -
Expanded Access of Omegaven IV Fat Emulsion to Infants and Children With PNALD
|
||
Approved for marketing |
NCT02780193 -
Intravenous Fish Oils in the Treatment of Parenteral Nutrition Liver Injury
|
||
Approved for marketing |
NCT01412359 -
Compassionate Use of Omegaven® in the Treatment of Parenteral Nutrition Associated Hepatic Injury
|